This study plans to learn more about the effects of a medicine called ruxolitinib on the
progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Ruxolitinib is FDA-approved for
the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. This study
intends to define the impact of ruxolitinib on the severity and progression of COVID-19. This
drug might to lower the hyperinflammation caused by the virus, which would prevent damage to
the lungs and possibly other organs.
The study will recruit patients who have been diagnosed with COVID-19.
The goal is to recruit 80 patients.